You are here: Industry Insights > Biogen

News List

Alkermes licences experimental MS therapy to Biogen pharmatimes
November 30, 2017
Dublin, Ireland-based Alkermes has licensed ALKS 8700, a novel, oral, small drug molecule in Phase III development for relapsing forms of multiple sclerosis, to US biotech Biogen.
Biogen Forges $278M MS Tie-Up With Alkermes biospace
November 28, 2017
Biogen and Alkermes Announce License and Collaboration Agreement to Develop and Commercialize ALKS 8700 for the Treatment of Multiple Sclerosis
Biogen Appoints Executive Vice President, Head of Global Marketing, Market Access and Customer Innov americanpharmaceuticacreview
November 06, 2017
Biogen announced the appointment of Chirfi Guindo as Executive Vice President and Head of Global Marketing, Market Access and Customer Innovation.
Eisai banks on potential of Biogen’s Alzheimer’s drug pharmafile
October 25, 2017
Drug developers investigating Alzheimer’s drugs know that they’re taking a gamble; there have been numerous big failures that have caused larger companies to shy away from the difficult-to-treat area.
Biogen takes up option to co-develop Eisai AD drug pharmatimes
October 25, 2017
Biogen and Eisai have expanded their existing collaboration agreement to develop and commercialise investigational therapies for Alzheimer’s Disease.
Vir Biotech blasts out of the blocks, with $500m in bank pharmafile
October 20, 2017
All has been quiet since former Biogen CEO, George Scangos, departed the company and then set up Vir Biotechnology in January
Genomics and Biogen partner to discover new multiple sclerosis treatments pharmaceufical-technology
October 18, 2017
UK-based company Genomics has entered a collaborative deal with US-based biotechnology firm Biogen to discover new treatments for multiple sclerosis (MS).
Biogen, Samsung Humira copy wins EU approval fiercepharma
August 28, 2017
A second biosimilar of AbbVie's Humira, the world's top-selling drug at $16 billion, has been approved in Europe.
Biogen MS drug hit by EU safety restriction pharmaphorum
July 11, 2017
Biogen’s Zinbryta multiple sclerosis drug has suffered a serious setback after European regulators restricted its use because of liver safety concerns.
What Makes Biogen (BIIB) and Bristol-Myers Squibb (BMS Such Attractive Takeover Targets BioSpace.com
June 28, 2017
Merger-and-acquisition activity is expected to pick up for the last half of this year. This is based largely on the loss of prominent patents in the biopharma industry, and what appears to be a build-up of cash reserves.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page